Immunotherapy succeeds in treating several refractory cancers

Release date: 2016-06-07

The results of several clinical trials published on June 5, 2016 indicate that immunotherapy has potential for change in the treatment of refractory advanced cancers such as bladder cancer and lung cancer.

A clinical trial confirmed that the drug Tecentriq (also known as atezolizumab), a drug developed by Swiss pharmaceutical giant Roche's Genentech, can make a quarter of the 119 patients tested. The advanced bladder tumor of the person has atrophy and the median survival time is nearly 15 months. The researchers say these results are comparable to the 9 to 10 months of survival typically achieved with chemotherapy.

The findings were presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Tecentriq allows patients to attack the cancer cells by the immune system and has been shown to be effective in treating patients with advanced bladder cancer who are less responsive to chemotherapy.

The study's author and Dr. Arjun Vasant Balar, assistant professor of medicine at New York University, said, "Up to half of patients with advanced bladder cancer are too weak to receive the only known prolonged survival therapy (Editor's Note: Chemotherapy)."

Balar said, "We are encouraged to observe that atezolizumab immunotherapy may help address this important unmet need."

The US FDA recently accelerated the approval of Tecentriq sales based on preliminary results from this clinical trial.

Charles Ryan, a professor of clinical medicine and urology at the University of California, San Francisco, who participated in the study, said, "This approach and other immunotherapies have given new impetus to the treatment of bladder cancer. In the past 10 years, bladder cancer treatment has actually No progress has been made in treatment."

Ryan said, "In fact, this kind of immunotherapy seems to be safe for the elderly patients -- they often have better treatment options -- which is even more inspiring."

The researchers plan to conduct a broader clinical trial using Tecentriq as the first treatment for advanced bladder cancer. Bladder cancer mainly affects the elderly, and most of them are smokers or former smokers.

Promising treatment

According to the results of another clinical trial involving 74 patients published at the American Society of Clinical Oncology in 2016, a new immunotherapeutic drug combined with a drug that kills cancer cells has also proven to be the most invasive treatment. Sexual lung cancer patients, the most invasive lung cancer accounted for 10 to 15% of all lung cancer.

The combination therapy Rova-T (rovalpituzumab tesirine) was developed by the emerging company Stemcentrx, which was recently acquired by AbbVie.

This combination therapy blocked tumor growth in 89% of patients with higher DLL3 protein levels, resulting in 39% of cancer regression in the tested patient population.

The main research author, Charles Rudin, a clinical oncologist at the Memorial Sloan Kettering Cancer Center, said, "In recent years, we have rarely seen successful treatments in the treatment of small cell lung cancer. Make these early treatment results even more inspiring."

A European study, also published in the 2016 American Society of Clinical Oncology, provides an inspiring result of an immunotherapeutic drug targeting claudine 18.2 for the treatment of advanced gastric cancer.

This immunotherapeutic drug is IMAB362 (an antibody drug) developed by Ganymed Pharmaceuticals of Germany and is also used in combination with chemotherapy.

This clinical trial of 161 patients with invasive gastric cancer showed that this antibody significantly prolonged their survival (13.2 months, or 16.7 months) when combined with chemotherapy, while survival was treated with chemotherapy alone. 8.4 or 9 months.

Source: Bio Valley

Rechargeable Hearing Aid

Shenzhen Sunshine Technology Co.,Ltd , https://www.szyatwin.com